Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPACA-MC: Piperacillin/Tazobactam vs Ceftriaxone + Metronidazole for Pediatric Perforated Appendicitis
NCT07869095Phase 3Not yet recruiting
- Sponsor
- McMaster Children's Hospital
- Start
- Apr 2027
- Primary completion
- Dec 2031
01
Overview
A Phase 3 trial of piperacillin + tazobactam in perforated appendicitis, sponsored by McMaster Children's Hospital. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
perforated appendicitis
Beyond the preview
Go deeper on NCT07869095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869095.